A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 microg/h, 100 microg/h, 50 microg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF).

Trial Profile

A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 microg/h, 100 microg/h, 50 microg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Cinaciguat (Primary)
  • Indications Decompensated heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COMPOSE-1
  • Most Recent Events

    • 13 Feb 2012 Planned end date changed from 1 Feb 2012 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 25 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Feb 2011 Planned end date changed from 1 Jan 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top